ArticleScientific reports2025
Risk factors for and incidence of osteoporosis in patients with breast cancer by gender : a nationwide cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of osteoporosis and fracture among patients with breast cancer: a systematic review and meta-analysis of cohort studies.Frontiers in oncology · 2026Pooled it
- [Genetic, endocrine, drug-induced and pancreatogenic forms of diabetes and exocrine pancreatic insufficiency (Update 2026)].Wiener klinische Wochenschrift · 2026Review
- A multicenter prospective matched comparative study on osteoporosis risk in cancer patients receiving chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is common in breast cancer patients, but gender-specific research on its incidence and risk factors is limited. This study examined the incidence and risk of osteoporosis in male and female breast cancer patients and analyzed the risk factors for fractures. This nationwide retrospective cohort study used data from the Korean National Insurance database, identifying invasive breast cancer patients from January 2009 to December 2015.Overall, 80,661 participants (299 males ; 80,362 females) were included. Matching was performed at a 1:5 ratio, based on age, treatment modalities and Charlson Comorbidity Index scores [CCI], resulting in 294 males and 1,470 females.Before and after matching, females consistently showed higher osteoporosis prevalence than males (16.7% vs. 5.0% before, 27.6% vs. 4.8% after, p < 0.001). Before matching, hip or vertebral fractures incidence showed no difference (1.2% vs. 1.3%, p = 0.789), but after matching, a significant difference was observed. (4.0% vs. 1.0%, p = 0.011). Endocrine therapy increased osteoporosis risk, particularly among females (hazard ratio [HR], 6.37; 95% confidence interval [CI], 3.74-10.89; p < 0.001). Age, steroid use, and CCI score were significant risk factors for osteoporosis. Adjusting for other variables, females with osteoporosis had a higher hip or vertebral fracture risk than males (HR, 3.96; 95% CI, 1.24-12.64; p = 0.020). Our study highlights gender-specific risks for osteoporosis and fractures in breast cancer patients, contributing to a comprehensive understanding for improving long-term outcomes and quality of life in survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.